Faslodex Post Marketing Surveillance
N/A
N/A
N/A
N/A
N/A
Open (Enrolling)
Female
Breast Cancer
Female
Breast Cancer
Trial Information
Faslodex Post Marketing Surveillance
Inclusion Criteria:
- Postmenopausal women
- Patients who have failed 2 or more prior hormone therapies (The prior hormone
therapies should contain both antiestrogen and non-steroidal Aromatase inhibitor)
- Patients who were intolerant to prior hormone therapy and have no endocrine
therapeutic options (The prior hormone therapies should contain both antiestrogen and
non-steroidal Aromatase inhibitor)
Exclusion Criteria:
- The patients who received Faslodex treatment before
Type of Study:
Observational
Study Design:
Time Perspective: Prospective
Outcome Measure:
Adverse events are confirmed by investigator through asking to patients or patients' voluntary reporting.
Outcome Time Frame:
5 years
Safety Issue:
No
Authority:
Korea: Food and Drug Administration
Study ID:
D6997L00018
NCT ID:
NCT00860561
Start Date:
February 2009
Completion Date:
October 2013
Related Keywords:
- Breast Cancer
- Efficacy profile
- Safety profile
- Faslodex
- Breast Neoplasms
Name | Location |
|---|
